Testing the Effect of a Warning About New Drugs

Not Applicable

Completed

• Conditions: Risk Communication
• Interventions: Other: Presentation of information about drug approval and level of warning

• Registration Number: NCT00950131
• Lead Sponsor: White River Junction Veterans Affairs Medical Center

Brief Summary

The purpose of this study is to test whether a new drug warning decreases enthusiasm for new drugs.

Detailed Description

Not available

Study Timeline

• Status Verified: 2009-07
• Study First Submitted: 2009-07-30
• Study First Submitted QC: 2009-07-30
• Study First Posted: 2009-07-31
• Study Start: 2009-08
• Primary Completion: 2009-08
• Study Completion: 2009-09
• Last Update Submitted: 2010-04-08
• Last Update Posted: 2010-04-09

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 2944

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Directive new drug warning	Presentation of information about drug approval and level of warning	Survey contains information about when the drug was approved by the FDA (2009)and a directive warning (i.e., stating the issue and why it matters) for new drugs. This directive warning mentions that serious drug side effects may emerge only after the drug is already on the market, and the reader should ask their doctor there is an available drug with a longer track record.
Non-directive new drug warning	Presentation of information about drug approval and level of warning	Survey contains information about when the drug was approved by the FDA (2009) and a non-directive warning (i.e., just stating the issue) for new drugs. This non-directive warning mentions only that serious drug side effects may emerge only after the drug is already on the market.
No new drug warning	Presentation of information about drug approval and level of warning	Survey contains information about when the drug was approved by the FDA (2009) only.

Primary Outcome Measures

Name	Time	Method
Hypothetical choice of old (vs. newer) drug	0 weeks (assessed during intervention)

Secondary Outcome Measures

Name	Time	Method
Comprehension of the drug warning and drug information	0 weeks (assessed during intervention)